Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Keratin 6C is a type II cytoskeletal protein belonging to the keratin family of intermediate filaments, encoded on chromosome 12q13. It forms heteropolymers in epithelial cells, providing a resilient framework that preserves tissue integrity, especially in the skin, hair follicles, and nails. Mutations in the KRT6C gene compromise intermediate filament assembly and cause rare skin disorders such as pachyonychia congenita and palmoplantar keratoderma, with symptoms including painful blisters and calluses, particularly on areas experiencing high friction. Recent research indicates that KRT6C or its circular RNA (circ-KRT6C) plays an oncogenic role in several epithelial-derived cancers, correlating with enhanced proliferation, immune evasion, and poor prognosis. Its dysregulated expression in cancer and response to environmental stress support its emerging role as a diagnostic biomarker.
Not applicable; no drugs directly targeting Keratin 6C are known, but alteration of its gene/protein expression can affect cellular responses in cancer and keratin disorders
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Keratin, type II cytoskeletal 6C (KRT6C).